Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.64 |
| ▸ | MAOB | P27338 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 5/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | PEPD | P12955 | 1/20 | 0.62 |
| ▸ | CA12 | O43570 | 1/20 | 0.62 |
| ▸ | BRD4 | O60885 | 1/20 | 0.62 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.62 |
| ▸ | CA1 | P00915 | 1/20 | 0.62 |
| ▸ | CA2 | P00918 | 1/20 | 0.62 |
| ▸ | MB | P02144 | 1/20 | 0.62 |
| ▸ | CA3 | P07451 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | RARG | P13631 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.62 |
| ▸ | CA4 | P22748 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23804045 | 0.93 | DEGS1 (0.61) | MAOAMAOBMAPTALDH1A1KMT2A | |
| SCHEMBL10778839 | 0.89 | SMN1; SMN2 (0.52) | MAOAMAOBMAPTKMT2ATSHR | |
| Hydrochloric Acid SCHEMBL11405284 | 0.86 | SMN1; SMN2 (0.50) | MAOAMAOBMAPTKMT2ATSHR | |
| SCHEMBL19988167 | 0.82 | CA12 (0.65) | MAPTALDH1A1KMT2AMEN1CA12 | |
| SCHEMBL11593321 | 0.81 | SMN1; SMN2 (0.67) | MAOAMAOBMAPTKMT2AMEN1 | |
| SCHEMBL6395775 | 0.81 | GAA (0.78) | MAOAMAOBMAPTALDH1A1KMT2A | |
| SCHEMBL28386018 | 0.81 | SMN1; SMN2 (0.61) | MAPTALDH1A1TSHRL3MBTL1KDM4E | |
| SCHEMBL11327346 | 0.81 | MAOA (0.82) | MAOAMAOBMAPTALDH1A1KMT2A | |
| SCHEMBL6394183 | 0.80 | ALDH1A1 (0.63) | MAOAMAOBMAPTALDH1A1KMT2A | |
| Acetaminophen SCHEMBL28267915 | 0.80 | KMT2A (0.95) | MAOAMAOBMAPTALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0142670-B1 | A PROCESS FOR THE PREPARATION OF KNOWN HERBICIDALLY ACTIVE PHENYL CARBAMATES | BEROL NOBEL (SUISSE) S.A. (CH) | 1990-05-23 | — | — | EP | claimed |
| US-4748265-A | Process for the preparation of herbicidally active phenyl carbamates | KEMISK VAERK KOGE A/S (DK) | 1988-05-31 | — | — | US | claimed |
| EP-0142670-A2 | A process for the preparation of known herbicidally active phenyl carbamates | BEROL NOBEL (SUISSE) S.A. (CH) | 1985-05-29 | — | — | EP | claimed |
| WO-1985001286-A1 | A PROCESS FOR THE PREPARATION OF HERBICIDALLY ACTIVE PHENYL CARBAMATES AND HERBICIDAL COMPOSITIONS CONTAINING THE SAME | KEMISK VA^ERK KO^/GE A/S (DK) | 1985-03-28 | — | — | WO | claimed |
| JP-9087241-A | — | — | None | — | — | JP | disclosed |
| WO-2025242903-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ONCO3R THERAPEUTICS BV (BE) | 2025-11-27 | — | — | WO | disclosed |
| US-20240238461-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | JANSSEN BIOTECH, INC. | 2024-07-18 | — | — | US | disclosed |
| WO-2024132001-A1 | MULTITARGET NUCLEAR RECEPTOR LIGANDS BASED ON 2-(4-(QUINOLIN-2-YLOXY)PHENOXY)PROPANOIC ACID AND 2-(4-(QUINOXALIN-2-YLOXY)PHENOXY)PROPANOIC ACID FOR THE TREATMENT OF METABOLIC AND LIVER DISEASES | CHARLES UNIVERSITY, FACULTY OF PHARMACY IN HRADEC KRALOVE (CZ) | 2024-06-27 | — | — | WO | disclosed |
| EP-4361163-A1 | PROTEIN INHIBITOR OR DEGRADING AGENT, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND PHARMACEUTICAL USE | JING MEDICINE TECHNOLOGY (SHANGHAI) LTD. (CN) | 2024-05-01 | — | — | EP | disclosed |
| US-20240101540-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | ABBVIE BIOTECHNOLOGY LTD (BM) | 2024-03-28 | — | — | US | disclosed |
| EP-4314005-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | Eli Lilly and Company (US) | 2024-02-07 | — | — | EP | disclosed |
| WO-2024026081-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | RIBON THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| US-4748265-A | Process for the preparation of herbicidally active phenyl carbamates | KEMISK VAERK KOGE A/S (DK) | 1988-05-31 | — | — | US | disclosed |
| EP-0242888-A2 | Stabilized liquid herbicidal composition and process for its preparation | Hoechst Schering AgrEvo GmbH (DE) | 1987-10-28 | — | — | EP | disclosed |
| EP-0142670-A2 | A process for the preparation of known herbicidally active phenyl carbamates | BEROL NOBEL (SUISSE) S.A. (CH) | 1985-05-29 | — | — | EP | disclosed |
| WO-1985001286-A1 | A PROCESS FOR THE PREPARATION OF HERBICIDALLY ACTIVE PHENYL CARBAMATES AND HERBICIDAL COMPOSITIONS CONTAINING THE SAME | KEMISK VA^ERK KO^/GE A/S (DK) | 1985-03-28 | — | — | WO | disclosed |
| WO-1985001286-A1 | A PROCESS FOR THE PREPARATION OF HERBICIDALLY ACTIVE PHENYL CARBAMATES AND HERBICIDAL COMPOSITIONS CONTAINING THE SAME | KEMISK VA^ERK KO^/GE A/S (DK) | 1985-03-28 | — | — | WO | disclosed |
| US-3997325-A | (Alkynyloxy)alkyl and (alkenyloxy)alkyl carbamates and their use as herbicides | AMERICAN CYANAMID COMPANY (US) | 1976-12-14 | — | — | US | disclosed |
| US-3951660-A | HETEROCYCLIC TONER COMPOUND | AGFA-GEVAERT, A.G. (DT) | 1976-04-20 | — | — | US | disclosed |
| US-3933507-A | LIGHT INSENSITIVE SILVER SALT, POLYMETHINE SENSITIZER | AGFA-GEVAERT, A.G. (DT) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238461-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | BDNF, CD47, MAG | MAOA 1149/4885MAOB 1115/4885MAPT 140/4885 |
| US-20240101540-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | PARP14, PARP15, PARP16 | MAOA 3730/4885MAOB 3997/4885MAPT 2494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.